Accumulation of nanocarriers in the ovary: a neglected toxicity risk?

Andreas Schädlich, Stefan Hoffmann, Thomas Mueller, Henrike Caysa, Cornelia Rose, Achim Göpferich, Jun Li, Judith Kuntsche, Karsten Mäder

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Several nanocarrier systems are frequently used in modern pharmaceutical therapies. Within this study a potential toxicity risk of all nanoscaled drug delivery systems was found. An accumulation of several structurally different nanocarriers but not of soluble polymers was detected in rodent ovaries after intravenous (i.v.) administration. Studies in different mouse species and Wistar rats were conducted and a high local accumulation of nanoparticles, nanocapsules and nanoemulsions in specific locations of the ovaries was found in all animals. We characterised the enrichment by in vivo and ex vivo multispectral fluorescence imaging and confocal laser scanning microscopy. The findings of this study emphasise the role of early and comprehensive in vivo studies in pharmaceutical research. Nanocarrier accumulation in the ovaries may also comprise an important toxicity issue in humans but the results might as well open a new field of targeted ovarian therapies.
Original languageEnglish
JournalJournal of Controlled Release
Volume160
Issue number1
Pages (from-to)105-112
ISSN0168-3659
DOIs
Publication statusPublished - 2012

Keywords

  • Animals
  • Drug Carriers
  • Female
  • Fluorescent Dyes
  • Fluorometry
  • Injections, Intravenous
  • Male
  • Mice
  • Mice, Inbred Strains
  • Microscopy, Confocal
  • Nanoparticles
  • Ovary
  • Particle Size
  • Rats
  • Rats, Wistar
  • Risk
  • Species Specificity
  • Testis
  • Tissue Distribution

Fingerprint

Dive into the research topics of 'Accumulation of nanocarriers in the ovary: a neglected toxicity risk?'. Together they form a unique fingerprint.

Cite this